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ABSTRACT
Importance: There is a lack of information about
long-term results of chronic angle closure glaucoma
following an acute primary angle closure attack in
Caucasian patients.
Purpose: The aim of the study was to report morpho-
logical and functional long-term data of chronic an-
gle closure eyes following a monolateral primary
angle closure attack and to provide a comparison
with their fellow eyes.
Design: Observational retrospective case series.
Participants: Fifty-seven consecutive patients (114
eyes) underwent long-term follow-up analysis.
Methods: Patients underwent ophthalmic assessment
more than 5 years since the angle closure attack.
Main Outcome Measures: Intraocular pressure, best-
corrected visual acuity, angle assessment, vertical C/
D ratio and standard automated perimetry were the
main outcome measures. Comparisons were made
between angle closure attack eyes and fellow eyes
and between phakic and pseudophakic eyes.
Results: Mean follow-up time was 5.86 ± 1.19 years.
A significant greater damage in the angle closure
eyes compared with fellow eyes in both structural
(mean C/D 0.61 ± 0.16; P < 0.001) and functional
(mean deviation: 7.98 ± 6.46 vs. 4.83 ± 4.95 dB;
P < 0.001) terms was present. Mean IOP was 13.44
± 2.78 and 13.89 ± 2.60 mmHg in angle closure
and fellow eyes (P = 0.11). Thirty of 57 (53%) fellow
eyes developed chronic angle closure (mean devia-
tion: 7.74 ± 5.21 dB) even if prophylactic iridotomy
was promptly performed.
Conclusion and Relevance: Our study prompts
ophthalmologists to closely follow patients after an
APAC attack to prevent potential glaucoma damage
in both APAC and fellow eye.
Key words: APAC, glaucoma, long-term follow-up, out-
come, PACG.
INTRODUCTION
Primary angle closure glaucoma (PACG) is one of the
leading causes of blindness worldwide, with a
pooled prevalence ranging from 0.46% in India to
1.19% in Japan.1 Although PACG is more diffuse
and studied in the Asian population, its incidence is
substantial even among Caucasians accounting for
0.4% of people older than 40 years.2 Moreover,
PACG incidence in Caucasians seems to be
underestimated as underlined by Ng et al. who found
an incidence of 14.8 per 100 000 in a Scottish
Caucasian cohort.3 As PACG prevalence is correlated
with age, it will be more diffuse in the western
countries as the population ages. It has been esti-
mated that the worldwide population with PACG
will rise by a third of the total glaucomatous in
2020,4 with 34 million people affected in 2040.5
Furthermore, the prevalence of glaucoma-related bi-
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lateral versus monolateral blindness is significantly
higher in PACG than in primary open angle
glaucoma.6
Acute primary angle closure (APAC) is a highly
symptomatic disease characterized by a sudden intra-
ocular pressure (IOP) elevation often associated with
severe ocular pain and systemic symptoms.7 Persis-
tent high IOP values following an APAC can lead to
irreversible glaucomatous optic neuropathy and
subsequent vision loss. It has been estimated that
up to 50% of eyes after an APAC episode develop
PACG.8
Being mainly a bilateral condition, attention is
commonly given to preserve the fellow eye from
potential risks, especially after an APAC episode.
It has been demonstrated that fellow eyes have a
significant risk of developing APAC: 2.5% of fellow
eyes in an Asian population were diagnosed with
PACG at the time of the acute attack, and an addi-
tional 6.5% developed glaucoma in the next
6 years.9
Although extensive research has been conducted
in the last few years on the long-term morbidity and
progression to PACG in Asian individuals following
APAC, limited data are available in the Caucasian
population. The aim of this cross-sectional observa-
tional case series was to provide a morphological
and functional assessment of PACG in Caucasian pa-
tients more than 5 years after the occurrence of a
monolateral APAC episode.
METHODS
The study was approved by the local ethics commit-
tee, and the authors declare no financial or proprie-
tary interests in the subject of this research. All
study procedures adhered to the Declaration of
Helsinki (as revised in Brazil 2013) for research
involving humans, and written informed consent
was obtained from the study subjects.
The study was conducted at the Eye Hospital of
Turin, the biggest in Piedmont (North-Western
Italy). In its emergency department, more than
30 000 visits occur every year, and it represents the
reference for about one-third of the 4.5 million
people living in Piedmont. Subjects in this study
had been previously visited at the Emergency
Department of the Eye Hospital and were treated
according to the Hospital Protocol, which advocates
medical management to promptly reduce the IOP
followed by bilateral YAG laser peripheral
iridotomies (LPIs). Lens extraction/glaucoma surgery
according to the clinical appearance of the angle is
performed if LPI and medical treatment are not
sufficient to obtain an adequate IOP control.
Consecutive Caucasian patients with chronic angle
closure glaucoma (CACG), who had suffered a
previousmonolateral episode of APAC at least 5 years
before, were included. Patients were aged between
50 and 80 years and were recruited either from our
Glaucoma Service or called back based on the list of
patients with APAC who had previously attended
the Emergency Department. Follow-up visits were
performed between September 2015 and September
2016. The patients who had not been recruited from
our Glaucoma Service first underwent a telephonic
interview to ascertain if they were suffering from
glaucoma after the APAC episode and then called
back for a follow-up visit.
A previous APAC episode was defined using the
following criteria:
1. presenting IOP of more than 28 mmHg on
Goldmann applanation tonometry;
2. presence of at least two of the following symp-
toms: ocular or periocular pain, nausea, vomiting
and an antecedent history of intermittent blurred
vision; and
3. presence of at least three of the following signs:
conjunctival injection, corneal oedema, mid-
dilated non-reactive pupil and shallow anterior
chamber.
Chronic angle closure glaucoma was diagnosed
based on the presence of a closed angle on indentation
gonioscopy (grade 0–1 Shaffer grade, ≥180 deg), ab-
normal visual field according to the Hodapp–Parrish–
Anderson10 criteria and glaucomatous optic neuropa-
thy. All visual fields underwent a second classification
according to Glaucoma Staging System 2.11
Exclusion criteria were bilateral APAC attack, sec-
ondary angle closure, previous intraocular surgery,
reported history of pre-existing glaucoma at the time
of APAC and incomplete clinical data.
Demographic characteristics, and medical and
ophthalmic history were gathered by a trained inter-
viewer using a pre-defined questionnaire. Ophthal-
mology records regarding the APAC attack and
management were reviewed, and medical charts
were further analysed. Type and time of interven-
tions after APAC were recorded.
A complete ophthalmic examination was prospec-
tively performed for each patient and included
logMAR best-corrected visual acuity, slit-lamp
biomicroscopy, gonioscopy, Goldmann applanation
tonometry and fundus assessment. Gonioscopy was
performed to obtain the mean gonioscopic angle
width (calculated by adding the Shaffer grade in
each of four quadrants and dividing by four) and to
assess for the presence of peripheral anterior
synechiae. Fundus assessment was performed
through a well-dilated pupil and a 78 D indirect lens.
Optic disc analysis included the evaluation of the
vertical cup:disc ratio and the neuroretinal rim. All
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examinations were performed by an expert ophthal-
mologist (T. R.).
Patients’ assessment also included ultrasound
pachymetry to measure the central corneal thickness,
corneal endothelial cell count with specular micros-
copy (CellChek Specular Microscope, Konan
Medical, Nishinomiya, Hyogo, Japan), axial length
(AL) and anterior chamber depth (ACD) measured
with IOL Master 500 Optical Biometry (Carl Zeiss
Meditec, Jena, Germany) and automated visual field
test with the Humphrey Field Analyzer (Carl Zeiss
Meditec).
Visual field analysis
Standard automated perimetry was performed with
the Swedish Interactive Threshold Algorithm
Standard strategy, programme 24-2 of the Humphrey
Field Analyzer (Carl Zeiss Meditec). The criteria used
for reliability were fixation losses ≤20%, false
positives, and false negatives ≤33%.
Corneal endothelial cell count with
specular microscopy
Specular microscopy images were obtained with the
CellChek Specular Microscope (Konan Medical). Im-
age analysis was performed using the semiautomated
centre technique. Only high-quality images were
included, and a manual count of the cells was
performed. Over 100 contiguous endothelial cells
were marked for the analysis.
Biometric factors with optical biometry
Biometry based on partial coherence interferometry
was performed using the IOL Master 500 (Carl Zeiss
Meditec). The AL was measured from the tear film to
the retinal pigment epithelium using a modified
Michelson interferometer that creates a pair of coaxial
780-nm infrared light beams with a coherence length
of about 130 nm. The ACD was defined as the
distance from the anterior corneal surface to the
anterior lens surface using lateral slit illumination at
approximately 30° to the optical axis. Five separate
measurements were averaged for AL and ACD
measurements.
Ultrasound pachymetry
Central corneal thickness was measured using ultra-
sound pachymetry (SW 1000 A-Scan Pachymeter,
Tianjin Suowei Electronic Technology, Tianjin,
China) after the instillation of one drop of topical
anaesthesia (0.4% oxybuprocaine hydrochloride);
the examiner manually placed the probe pachymeter
as perpendicularly as possible to the centre of the
cornea while the patient was asked to gaze a distant
fixation target straight ahead. The mean of five
measurements was then calculated.
Statistical analysis
Continuous variables were checked to meet the
normality conditions of Shapiro–Wilk test. Nonpara-
metric tests were used: the Wilcoxon signed rank test
for comparisons of two correlated samples involving
matched pairs and the Mann–Whitney test for
comparisons of two independent distributions.
The binary variables were arranged in cross-
correlation tables and studied using the chi-squared
test with the Yates correction.
The relationship between presenting features
(presenting IOP and duration of acute attack) and
structural and functional findings was examined
using linear regression analysis and the Spearman’s
rank correlation coefficient.
Statistical analysis was performed using a statis-
tical software (SPSS Statistics, version 19.0, Chi-
cago, IL, USA). Statistical significance was set at
P < 0.05.
Definition
In the paper, the eye that previously suffered APAC
will be defined as the affected eye, and the contrala-
teral eye as the fellow eye, irrespective of the pres-
ence of PACG.
RESULTS
Baseline data
Seventy consecutive patients with previous APAC
were enrolled. Eight patients were excluded owing
to unavailability of data from the APAC episode,
whereas five patients called from our Emergency
Department lists were excluded owing to the inclu-
sion criteria for PACG not being met (three absence
of significant disk damage and two inconsistent
visual field defects). Fifty-seven CACG patients were
analysed in terms of structural and functional damage
at a mean of 5.86 ± 1.19 years (range 5–9 years) after
APAC.
Demographic data are summarized in Table 1.
The most common symptom of presentation was
ocular pain (76% of subjects) followed by blurred
vision (71%), ocular hyperemia (21%), nausea
(20%) and vomiting (14%).
All the patients were treated medically to resolve
the attack. Whenever possible, LPI was performed
within 24 h from presentation in the Emergency
Department (22 eyes). In 32 eyes, it was deferred
but performed within 48 h. In three eyes (5%),
the IOP was insufficiently controlled by medical
therapy, and LPI was impossible to perform owing
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to corneal haziness, and phaco-emulsification with
epithelial removal was performed. LPI was per-
formed in the fellow eye of all patients as a prophy-
lactic intervention. No serious complications were
reported to have occurred after laser iridotomy in
any eye.
Follow-up data
Data from affected and fellow eyes at last follow-up
are reported in Table 2.
Mean IOP at the time of follow-up was respec-
tively 13.44 ± 2.78 and 13.89 ± 2.60 mmHg in the af-
fected and fellow eyes. All the eyes presented an
IOP < 21 mmHg, whereas 86% and 72% of affected
eyes and 89% and 77% of fellow eyes had an
IOP < 18 and <16 mmHg, respectively. Data about
IOP and medication status are provided in Table 3.
All iridotomies were patent at the follow-up and,
no APAC recurrencies were reported in either the
affected or fellow eyes.
The mean time after APAC to phaco-emulsification
was 35.24 ± 12.07 months in the affected eyes and
45.65 ± 11.19 months in the fellow eyes. This
difference was statistically significant (P = 0.012).
None of the eyes required additional glaucoma
surgery.
Tables 4, 5 and 6 represented respectively the dis-
tribution of vertical cup:disc ratio and of visual field
damage in affected and fellow eyes.
Table 1. Patients characteristics and management at the time of APAC
Study subjects (n = 57)
Mean ± SD Range
Age (years) 68.84 ± 9.60 50–80
Gender, F/M, n (%) 42/15 (74%/26%)
Presenting IOP (mmHg) 53.19 ± 9.15 30–70
Duration of acute attack (hours) 22.07 ± 18.42 2–72
Medications used for acute attack (n/patient) 3.77 ± 0.85 2–6
Topical medications (n/patient) 2.70 ± 0.53 2–4
Systemic medications (n/patient) 1.07 ± 0.75 0–2
Phakic patients at the time of APAC, n (%) 57 (100%)
LPI in the APAC eye, n (%) 54 (95%)
LPI within 24 h from the presentation in the emergency department 22 (39%)
LPI within 48 h from the presentation in the emergency department 32 (56%)
Phaco-emulsification to resolve APAC 3 (5%)
LPI in fellow eye, n (%) 57 (100%)
SD, standard deviation; F, female; M, male; IOP, intraocular pressure; APAC, acute primary angle closure; LPI, laser peripheral
iridotomy.
Table 2. Characteristics of the enrolled eyes at last examination
APAC eye Fellow eye P-value
Vertical C/D ratio 0.68 ± 0.15 (0.4–0.9) 0.61 ± 0.16 (0.3–0.9) <0.0001†
MD (dB) 7.98 ± 6.46 (0.9–26.8) 4.83 ± 4.95 (1.24–23.6) <0.0001†
PSD (dB) 5.17 ± 3.38 (1.15–14.33) 3.43 ± 2.24 (0.23–11.9) <0.0001†
BCVA, logMAR 0.37 ± 0.49 (0–1.7) 0.17 ± 0.20 (0–1) <0.0001†
ECD (cells/mm2) 1923.93 ± 497.08 (673–3300) 2066.02 ± 429.70 (1028–2994) 0.002†
CCT (μm) 551.98 ± 39.09 (436–653) 551.98 ± 40.75 (450–669) 0.79†
ACD (mm) 2.58 ± 0.70 (1.28–4.57) 2.58 ± 0.70 (1.42–4.58) 0.65†
AL (mm) 21.68 ± 0.99 (18.88–24.21) 21.86 ± 1.17 (18.65–25.76) 0.013†
Gonioscopy, grade 1.44 ± 0.76 (0–3) 1.60 ± 0.78 (0–4) 0.029†
Gonioscopy PAS, eyes (%) 23/57 (40.35%) 10/57 (17.54%) 0.013‡
Lens status
Phakic 32 (56%) 39 (68%)
Pseudophakic 25 (44%) 18 (32%) 0.24‡
All parameters are expressed as mean ± standard deviation (range). BCVA, best-corrected visual acuity; ACD, anterior chamber
depth; AL, axial length; APAC, acute primary angle closure; MD, mean deviation; PAS, peripheral anterior synechiae; PSD, pattern
standard deviation; CCT, central corneal thickness; ECD, endothelial cell density.
†Wilcoxon test.
‡Chi-square test.
4 Fea et al.
© 2017 The Authors Clinical & Experimental Ophthalmology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian
and New Zealand College of Ophthalmologists
Five years outcomes after acute primary angle closure 235
Visual acuity (VA) at follow-up was 0.37 ± 0.48
logMAR in the affected eyes and 0.17 ± 0.20 logMAR
in the fellow eyes. The distribution of VA in the af-
fected eyes is presented in Figure 1.
The causes of VA ≥ 1 logMAR were cataract in one
patient, macular oedema in two eyes and severe glau-
coma damage in the remaining six eyes.
No statistically significant correlation was found
between presenting IOP or duration of APAC attack
and the structural and functional measurements at
last follow-up visit.
Fellow eye data
Of the 57 fellow eyes, 30 (53%) had glaucomatous
neuropathy at the time of the last follow-up; the
mean deviation (MD) was 7.74 ± 5.21 dB (range
3.14 to 23.6). Table 7 shows the comparison
between fellow CACG eyes and fellow healthy eyes.
Nine out of 27 non-CACG fellow eyes were on
therapy owing to ocular hypertension.
In order to evaluate the influence of phaco-
emulsification on the outcomes, we compared the
affected eyes that underwent phaco-emulsification
with the affected phakic eyes. Patients who
underwent phaco-emulsification were older than
the phakic patients (71.8 ± 9.27 and 66.53 ± 9.34,
P = 0.026), had lower mean IOP values and took less
anti-glaucomatous medications (IOP = 12.72 ± 2.32
with 0.68 ± 1.03 medications in the pseudophakic
eyes; IOP = 14.00 ± 3.01 with 1.59 ± 1.16 in the
phakic eyes, P = 0.13 for IOP, P = 0.001 for medica-
tion). Statistically significant differences emerged
also in terms of ACD and angle grading
(ACD = 2.82 ± 0.85, angle grading = 1.92 ± 0.77 in
pseudophakic eyes and ACD = 2.39 ± 0.50,
P = 0.034 angle grading = 1.06 ± 0.49, P < 0.001 in
phakic eyes).
DISCUSSION
Primary closed angle glaucoma is regarded as an
uncommon disease in Caucasian, and this accounts
for the lack of long-term data on the morbidity and
progression of this disease.
Our study focused on the long-term morphological
and functional outcomes in Caucasian who
Table 3. Long-term IOP and medication status in affected and fellow eyes
APAC eye Fellow eye P-value
IOP (mmHg) 13.44 ± 2.78 (9–19) 13.89 ± 2.60 (10–20) 0.38†
Medication-free eyes (%) 19/57 (33%) 31/57 (54%) 0.04‡
Medications (all eyes), n/eye 1.19 ± 1.19 0.73 ± 1.04 <0.001§
Medications in treated eyes, n/eye 1.79 ± 1.02 (1–5) 1.62 ± 0.98 (1–5) 0.45§
APAC, acute primary angle closure; IOP, intraocular pressure.
†Mann–Whitney test.
‡Chi-squared test.
§Wilcoxon test.
Table 4. Distribution (%) of vertical cup:disc ratio in affected
and fellow eyes
Vertical cup:disc ratio P†
<0.5 0.5–0.7 0.7–0.9 >0.9
APAC eyes 4 (7%) 25 (44%) 25 (44%) 3 (5%) 0.035
Fellow eyes 14 (25%) 26 (46%) 16 (28%) 1 (2%)
APAC, acute primary angle closure.
†Chi-squared test.
Table 5. Distribution (%) of visual field damage, according to
the Hodapp–Parrish–Anderson criteria in affected and fellow
eyes
Visual field damage (Hodapp–Parrish–Anderson) P†
No damage <6 dB 6–12 dB >12 dB
APAC eyes 3 (5%) 28 (49%) 13 (23%) 13 (23%) 0.02
Fellow eyes 10 (18%) 35 (61%) 7 (12%) 5 (9%)
†Chi-squared test.
Table 6. Distribution (%) of visual field damage, according to the GSS 2 in affected and fellow eyes
GSS 2 P†
Stage 0 Stage borderline Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
APAC eyes 4 (7%) 9 (16%) 9 (16%) 11 (19%) 11 (19%) 7 (12%) 6 (11%) 0.04
Fellow eyes 12 (21%) 6 (11%) 18 (32%) 10 (17%) 7 (12%) 2 (4%) 2 (4%)
APAC, acute primary angle closure; GSS 2, Glaucoma Staging System 2.
†Chi-squared test.
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developed a CACG in one eye following an APAC
attack. Clinically significant structural and functional
damage of both the affected and fellow eyes was
observed. In our relatively large cohort of patients,
almost half of the eyes that developed the acute
attack, when examined more than 5 years later,
presented in the affected eye a moderate to severe
visual field defect with both the Hodapp (46%) and
Brusini (42%) classifications.
The available data on the progression to PACG in
the affected eye of purely Caucasians are limited to
a single report by Andreatta12 on seven patients
who developed PACG 27 ± 14 months after an acute
attack.
Our data are similar to those of that study in
several respects as the IOP in the affected eye at the
last follow-up visit (13.44 ± 2.78 vs. 14 ± 2 mmHg),
the C/D (0.68 ± 0.15 vs. 0.69 ± 0.11), the MD
(7.98 ± 6.46 vs. 8.2 ± 2.8 dB) and in some respect
as the post-APAC management. In the study of
Andreatta, PACG patients underwent repeated LPI
and cataract extraction more frequently, and in one
patient, trabeculectomy was necessary, whereas only
57% of the PACG patients were on topical
medications.
The main difference is that Andreatta was able to
exclude the presence of a PACG before the occurrence
of the APAC attack because he had access to the optic
nerve and visual field data immediately after the
event.
The IOP at presentation and at the last visit in our
sample is in line with previous studies in Asian
or mixed populations. The mean presenting IOP in
the affected eye in our series (53.2 ± 9.2 mm Hg)
was similar to that found in Eastern Asians (Lee
et al.13,14: 50.2 ± 12.6 and 49.2 ± 14 mmHg) and
in a mixed New Zealand population (Chew et al.15:
53.3 ± 12.4 mmHg).
Considering the long-term follow-up data on the
affected eyes, 43 Asian PACG patients with a
previous APAC attack observed for an average of
6.3 years presented a more severe visual field defect
(MD: 11 ± 10.8 dB and pattern standard deviation:
4.1 ± 2.9 dB).8 Tham16 reported an MD of
14.7 ± 9.4 dB and a cup:disc ratio of 0.7 ± 0.2 in
13 eyes after an unspecified time period after the
attack, although this group of patients had a higher
IOP and medication use (17.8 ± 7.1 mmHg and
2.2 ± 0.9 drug/patient) compared with ours
(13.61 ± 2.84 mmHg and 1.24 ± 1.24 drug/patient).
Chen et al.,17 who reported similar IOP at the last
follow-up visit, found a more advanced optic nerve
damage (cup:disc ratio: 0.76 ± 0.14 and MD:
8.5 ± 6.65 dB) in 40 eyes, albeit with a shorter and
more variable follow-up (3 months to 8 years).
The management of our patients developing
CACG is somehow different from what is reported
by previous authors.8,13,18 The percentage of our
patients undergoing phaco-emulsification during
the follow-up was 39%, whereas no patients needed
additional glaucoma surgery. The percentage of
glaucoma surgery reported by other authors after
APAC is higher in both Caucasian and Asian
patients: 16% and 63% filtration surgeries were
respectively performed in the series by Andreatta12
and Alsagoff.18 Nevertheless, published studies in
White populations found LPI to be effective with a
low incidence of eventual trabeculectomy ranging
from 0% to 8%.19,20
Our data seem to confirm that the prognosis
of APAC is generally worse in Asians than in
Caucasians. Quek et al.21 found that in Chinese with
PACG, higher mean overall IOP and history of
previous APAC were positively correlated with
poorer visual field and visual acuity outcomes over
a 10 years’ period. Andreatta,12 within his APAC
Caucasians series, reported that a longer time to
resolve the APAC attack and a higher duration of
symptoms correlated with a poorer prognosis. We
could not confirm these findings, and this may be
Figure 1. Best-corrected visual acuity (number
of eyes and percentage) in eyes with previous
acute primary angle closure and fellow eye.
Chi-squared test, P = 0.04.
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due to the shorter duration of the attack in our patients.
Furthermore, LPI was performed within 48 h, and this
may have prevented IOP spikes. Other authors could
not find any correlation between the duration of the
symptoms and the long-term prognosis.8,14
As expected, the affected eye was more seriously
compromised compared with the fellow eye. The
difference between the affected eye and the fellow
eye was both structural (vertical C/D) and functional
(standard automated perimetry and VA).
In our series, more than 50% of the fellow eyes
(30/57) had CACG, although they underwent a
prophylactic LPI within 48 h after the APAC attack.
Twelve of the fellow eyes (21%) had a significant
visual field defect (more than 6 dB) according to the
Hodapp classification and 11 (19.3%) according to
Brusini’s classification. A visual acuity ≥1 logMar
determined by glaucoma was present in a single eye.
In Singapore, Friedman et al.9 found glaucomatous
optic nerve damage in seven out of 79 (8.9%) of
fellow eyes, 6.3 ± 1.5 years since APAC. In two eyes,
the glaucomatous optic neuropathy (GON) was pre-
existing before the attack. The MD (15.0 ± 11.9 dB
in six eyes) was higher than in our series
(4.83 ± 4.95 dB). The lower prevalence in the
Singapore Study can be explained by the stricter
criteria of definition of the GON used by the author.
Furthermore, owing to the design of our study, it
was impossible to determine if CACG in some of
the fellow eyes was determined by previous subacute
attacks or by an increase of the IOP during the
follow-up, although the latter seems less likely as
they underwent an LPI, which was patent and
presented an IOP within normal limits. If this is the
case, our case series underlines the fact that PACG is
largely underestimated and treated in Caucasian
patients.
Phaco-emulsification in our study was performed
at a mean of 35 months after the attack in the affected
eye and 45 months in the fellow eye. The affected
eyes that underwent phaco-emulsification had a sig-
nificantly lower use of medications. These findings
corroborate the efficacy of phaco-emulsification in
the management of patients with PACG, as recently
pointed out by the Eagle Clinical Trial.22
Our study has several limitations mainly due to its
retrospective nature. No or incomplete data regarding
the C/D ratio and the visual field defect at baseline
were available, no longitudinal data during the
follow-up were available, multiple ophthalmologists
were involved both in the initial management of the
APAC attack and between the attack and the last
follow-up visit, and the follow-up period was
variable. Nevertheless, our study has the advantage
of showing a snapshot of both the affected eye and
the fellow eye a reasonable time after the acute attack
in a Caucasian population living in a region with
prompt access to both the emergency and regular
follow-up visits. It also confirms that, although the
damage following an APAC attack seems less severe
in Caucasians, there is a consistent risk even for this
population to develop a significant visual damage
both in the affected eye and in the fellow eye.
Our study prompts ophthalmologists to closely
observe the patients with APAC to prevent potential
long-term harm to the optic nerve. It also suggests
Table 7. Clinical outcomes of fellow eyes divided on the basis of glaucomatous damage at the last follow-up
CACG eye (n = 30) Non-CACG eye (n = 27) P-value
Age (years) 72.90 ± 7.48 (50–80) 64.33 ± 9.79 (50–80) 0.001†
IOP (mmHg) 13.43 ± 2.75 (10–20) 14.41 ± 2.36 (10–20) 0.11†
Medications, n/patient 1.07 ± 1.26 (0–5) 0.37 ± 0.56 (0–2) 0.023†
Medication-free, eyes (%) 13/30 (43%) 18/27 (66%) 0.13‡
Lens status
Phakic 17 (57%) 22 (81%)
Pseudophakic 13 (43%) 5 (19%) 0.08‡
BCVA, logMAR 0.24 ± 0.24 (0–1) 0.09 ± 0.10 (0–0.4) 0.006†
MD (dB) 7.74 ± 5.21 (3.14–23.60) 1.61 ± 1.42 (1.24–4.03) <0.001†
PSD (dB) 4.70 ± 3.06 (1.50–11.90) 2.02 ± 1.13 (0.23–6.50) 0.004†
ECD 2021.63 ± 481.54 (1028–2923) 2115.33 ± 368.38 (1365–2994) 0.59†
Vertical C/D ratio 0.68 ± 0.14 (0.4–0.9) 0.53 ± 0.14 (0.3–0.8) <0.001†
ACD (mm) 2.78 ± 0.77 (1.43–4.58) 2.36 ± 0.54 (1.42–3.83) 0.012†
AL (mm) 21.83 ± 1.16 (18.65–24.04) 21.90 ± 1.20 (19.85–25.76) 0.707†
Gonioscopy, grade 1.70 ± 0.76 (0–3) 1.48 ± 0.80 (0–4) 0.17†
CCT (μm) 553.60 ± 48.78 (450–669) 550.19 ± 30.28 (488–615) 0.701†
Gonioscopy PAS, eyes (%) 7/30 (23.3%) 3/27 (11.1%) 0.39‡
ACD, anterior chamber depth; AL, axial length; MD, mean deviation; PAS, peripheral anterior synechiae; PSD, pattern standard
deviation.
†Mann–Whitney test.
‡Chi-squared test.
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that the incidence of glaucoma after APAC may be
underestimated in Caucasians. Our study is unique
as it investigates several parameters at least 5 years
after APAC in a purely Caucasian population.
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